20/20 Biolabs, Inc. (AIDX)
NASDAQ:AIDX
AIDX Stock Chart & Stats
$1.78
--
Market closed
$1.78
--
Day’s Range― - ―
52-Week Range$0.54 - $50.00
Previous CloseN/A
VolumeN/A
Average Volume (3M)N/A
Market Cap
$6.32M
Enterprise ValueN/A
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta2.83
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding10,611,528
10 Day Avg. VolumeN/A
30 Day Avg. VolumeN/A
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$3.39Price Target Upside90.63% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
20/20 Biolabs, Inc. News
AIDX FAQ
What was 20/20 Biolabs, Inc.’s price range in the past 12 months?
20/20 Biolabs, Inc. lowest stock price was $0.54 and its highest was $50.00 in the past 12 months.
What is 20/20 Biolabs, Inc.’s market cap?
20/20 Biolabs, Inc.’s market cap is $6.32M.
When is 20/20 Biolabs, Inc.’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were 20/20 Biolabs, Inc.’s earnings last quarter?
Currently, no data Available
Is 20/20 Biolabs, Inc. overvalued?
According to Wall Street analysts 20/20 Biolabs, Inc.’s price is currently Undervalued.
Does 20/20 Biolabs, Inc. pay dividends?
20/20 Biolabs, Inc. does not currently pay dividends.
What is 20/20 Biolabs, Inc.’s EPS estimate?
20/20 Biolabs, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does 20/20 Biolabs, Inc. have?
20/20 Biolabs, Inc. has 10,611,528 shares outstanding.
What happened to 20/20 Biolabs, Inc.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of 20/20 Biolabs, Inc.?
Currently, no hedge funds are holding shares in AIDX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
20/20 Biolabs, Inc.
20/20 GeneSystems, Inc. operates as a specialized clinical diagnostic company, focusing primarily on screening for cancer and analyzing viral infections. The firm offers advanced blood tests for the early detection of various cancers, including a notable product called OneTest. Additionally, it provides services for identifying viruses, such as rapid COVID-19 test kits like the Assure COVID-19 IgG/IgM rapid assay. The company also manages the Clinical Lab Innovation Axcelerator (CLIAx), a collaborative laboratory space designed to help developers of diagnostic products bring their innovations to the U.S. market. Furthermore, 20/20 GeneSystems delivers its cancer screening algorithm technology to healthcare providers via a software-as-a-service (SaaS) platform. It actively supports emerging diagnostic startups by offering them access to shared lab infrastructure and vital resources. Founded in 2000, the company is headquartered in Gaithersburg, Maryland.
AIDX Stock 12 Month Forecast
Average Price Target
$3.39
▲(90.63% Upside)
Ownership Overview
0.49% Insiders
<0.01% Other Institutional Investors
99.51% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---